Delcath Q2 revenue $7.8M vs $0.5M YoY; HEPZATO KIT generates $6.6M

DELCATH SYSTEMS, INC.

2024-Q2 EPS reported -$0.93 revenue$10,905,000

Revenue $7.8M ($6.6M HEPZATO US, $1.2M CHEMOSAT Europe) vs $0.5M prior year.
Cash and investments $19.9M; final principal payment submitted to Avenue Venture.
Activated 8 US treating centers; received CMS NTAP status for HEPZATO (Aug 1, 2024).
Appointed Dr. Bridget Martell to Board; extended melphalan supply agreement to 2028.
FOCUS study results published in Annals of Surgical Oncology; accepted for ESMO poster.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.